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Background: Endometriosis is regarded as a complex and heterogeneous disease in which genetic and environmental
factors contribute to the phenotype. The Vascular Endothelial Growth Factor (VEGF) plays important roles in the
pathogenesis of endometriosis. The present study was aimed at investigating the contribution of VEGF polymorphisms
as risk factors for the development of endometriosis. This is the first study to evaluate the combined influence of the
five most common VEGF polymorphisms.
Methods: This study was conducted at two hospitals from the Brazilian public health system, and comprised 294
women submitted to laparoscopic or laparotomy surgery: 182 patients had a histologically confirmed diagnosis of
endometriosis (cases), whereas 112 had no evidence of the disease (controls). The VEGF polymorphisms were
determined by TaqMan real-time polymerase chain reaction. The odds ratio (OR) with their 95% confidence intervals
(CI) were calculated using an unconditional logistic regression model.
Results: Endometriosis patients and controls did not differ regarding age distribution, whereas the body mass index
was significantly lower in endometriosis patients, when compared with controls (23.1 ± 3.9 versus 27.3 ± 5.9, P < 0.001).
The evaluation of gynecological symptoms, including dysmenorrhea, non-cyclic chronic pelvic pain, dyspareunia and
infertility, indicates significantly higher prevalences among endometriosis cases. The variant allele -1154A was
significantly associated with endometriosis, either considering all cases (OR: 1.90, 95% CI: 1.23–2.97), deep infiltrating
endometriosis (DIE) (OR: 1.83, 95% CI: 1.16-2.90) or moderate and severe endometriosis (stages III-IV) (OR: 1.97, 95%
CI: 1.21-3.19). No significant differences were found in allele or genotype distributions of the –2578C > A, −460 T >
C, +405G > C and +936C > T polymorphisms between endometriosis cases and controls. A total of six haplotypes
were inferred derived from four polymorphisms (−2578C > A, −460 T > C, −1154G > A and +405G > C). There was
a protective association between CCGG haplotype and endometriosis, either considering all cases (OR: 0.36, 95%
CI: 0.15–0.86), DIE (OR: 0.37 95% CI: 0.15 – 0.90) or stages III-IV (OR: 0.35 95% CI: 0.13 – 0.95).
Conclusions: The present results indicate a positive association between VEGF -1154G > A and the risk of
developing endometriosis, whereas the CCGG haplotype may be protective against the development of disease.
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Endometriosis is a benign estrogen-dependent disease,
characterized by the presence and growth of endometrial
tissue outside the uterus, and represents one of the most
common benign gynecological disorders nowadays [1].
This disease is associated with infertility, severe and in-
capacitating painful symptoms, including chronic pelvic
pain, dysmenorrhea and dyspareunia [2,3]. It has been
estimated that endometriosis affects 10% of women of
reproductive age, but the real prevalence may even be
higher because it is often not diagnosed due to its het-
erogeneous clinical manifestation [4]. Endometriosis fre-
quently produces serious effects on professional, social
and marital life [5].
Despite many investigations about endometriosis, the
pathogenesis of the disease remains unclear, although
the predominant theory is that it is due to retrograde
menstruation [6]. In addition, endometriotic lesions re-
quire an adequate blood supply to survive in their ec-
topic sites, and angiogenesis represents a crucial step
during this process [7]. The development of new blood
vessels is a complex dynamic process, which is regulated
by a signal sequence of different angiogenic factors. The
Vascular Endothelial Growth Factor (VEGF) is one of
the most potent angiogenic factors and several authors
postulated that it would be involved in the progress of
the ectopic lesions in endometriosis [8,9]. Accordingly,
our group demonstrated that VEGF-induced angiogen-
esis is a critical aspect in the pathophysiology of this
disease [10-12].
VEGF is encoded by the VEGF gene [13], which is poly-
morphic, with several single nucleotide polymorphisms
(SNPs) in regulatory regions [14]. Recently, there is grow-
ing interest in investigating if VEGF SNPs may affect the
inheritable susceptibility to endometriosis [15-18]. The
results are conflicting, possibly due to the diversity of
populations studied and because endometriosis is a het-
erogeneous disease [15]. In addition, no investigation re-
garding the susceptibility to endometriosis considered the
combined effect of the five most studied VEGF SNPs
(−2578C >A, −460 T > C, −1154G > A, +405G > C and
+936C > T) in their possible haplotypes.
In the present work, we aimed to describe the fre-
quency of alleles, genotypes and haplotypes of five VEGF
SNPs among Brazilian women, and to evaluate their im-
pact on endometriosis susceptibility.
Methods
Study population
The case–control study was approved by the Human
Research Ethics Committee of the Hospital das Clínicas –
Faculdade de Medicina – Universidade de São Paulo and
of the Hospital Federal dos Sevidores do Estado (Protocols
number 910/11 and 414/11, respectively). All participatingpatients (n = 294) provided written informed consent and
answered a questionnaire about their demographics and
preoperative painful symptoms. Data were obtained by in-
person interviews at two hospitals from the Brazilian pub-
lic health system, carried out from 2011 through 2013.
Patients assigned for laparoscopy or laparotomy for
gynecological procedures were considered eligible. In-
dividuals with any history or diagnosis of cancer or
adenomyosis were not included, since both are angiogenesis-
related pathologies [19,20]. One hundred eighty-two pa-
tients undergoing laparoscopy (n = 174) or laparotomy
(n = 8) for the diagnosis and treatment of endometriosis
were enrolled as cases. The diagnosis of endometriosis,
after their operative findings, was confirmed histologi-
cally, according to the presence of endometrial glands
and/or stroma in the lesions. According to the revised
American Fertility Society classification, 71 (39.0%) pa-
tients had minimal or mild endometriosis (stages I–II),
110 (60.4%) had moderate or severe endometriosis
(stages III–IV) and 1 (0.6%) had these information miss-
ing. According to Nisolle and Donnez [21] three types
of disease must be considered: superficial endometriosis
(SUP), ovarian endometrioma (OMA) and DIE. The dis-
tribution of endometriotic patients according to their
worst endometriotic lesion was as follows: SUP (14
patients; 7.7%), OMA (17 patients; 9.3%) and DIE (151
patients; 83.0%).
Controls (n = 112) were patients without visible endo-
metriosis at surgery and who reported no previous diagno-
sis of endometriosis. In the control group, surgical
laparoscopy (n = 106) or laparotomy (n = 6) was proposed
in order to perform tubal ligation (n = 51) or treatment of
benign diseases, such as ovarian cysts (n = 22), myoma
(n = 10), hydrosalpinx (n = 8) or other reasons (n = 21).
The body mass index (BMI) was calculated as the
weight (kg) divided by the square of height (m2). Ac-
cording to WHO’s expert committee [22], the weight
status is classified into five groups: underweight (BMI <
18.5), normal weight (18.5 ≤ BMI ≤ 24.9), overweight
(25 ≤ BMI ≤ 29.9), obesity (30 ≤ BMI < 40) and morbid
obesity (BMI ≥ 40).
The present study focused specifically on objective
symptoms, such as dysmenorrhea, chronic pelvic pain,
deep dyspareunia and infertility. As suggested in our
previous report [3], only severe and incapacitating symp-
toms of pain were included for statistical analysis pur-
poses. Infertility (primary or secondary) was defined by
the couple not being able to conceive after one year of
regular, contraceptive-free intercourse.
VEGF genotyping
Peripheral blood samples (3 mL) were collected in
EDTA tubes, and DNA was extracted by using a com-
mercial kit (Genomic DNA Extraction, Real Biotech
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A validated TaqMan assay (VIC- and FAM-labeled) for de-
tection of each VEGF -2578C > A (rs699947), −460 T>
C (rs833061), −1154G>A (rs1570360), +405G>C (rs2010963),
+936C > T (rs3025039) SNPs was purchased from Applied
Biosystems. Table 1 summarizes the sets of probes and
primers used for each analysis. PCR amplification for
all SNPs was performed in 8 μL reactions with 30 ng
of template DNA, 1× TaqMan Universal Master Mix (Ap-
plied Biosystems, Foster City, CA, USA), 1× each primer
and probe assay, and H2O q.s. Thermal cycling was ini-
tiated with a first denaturation step of 10 min at 95°C,
followed by 40 cycles of denaturation at 92°C for 15 s
and annealing at 60°C for 1 min. The allele-detection
process was performed on a 7500 Real-Time System
(Applied Biosystems, Foster City, CA, USA) to determine
the allelic discrimination.
Statistical analysis
Comparisons of age and BMI in the study groups were
performed using the Stundent’s t test, and data were pre-
sented as mean ± standard deviation (SD). Otherwise,
the nominal data, such as spontaneous abortion, parity,
infertility and preoperative painful symptoms, as well as
the categories of BMI, were expressed as percentages
and evaluated by Chi-Square Test or Fisher’s exact test,
where applicable.
Deviations from Hardy–Weinberg equilibrium (HWE)
were assessed by the goodness-of-fit χ2 test. VEGF allele
frequency and genotype distribution were derived by
gene counting. Allele and genotype frequencies between
the groups were compared using the χ2 test or, when ap-
propriate, the Fisher’s exact test. The haplotype patterns
and linkage disequilibrium coefficients (D’ is degree of
imbalance in module and R2 is degree of correlation)
were inferred using Haploview [23], based on the algo-
rithm of expectation and maximization [24]. The riskTable 1 Characterization of VEGF polymorphisms, probes and
PCR
Identified SNP TaqMan assays Region
rs699947 C_8311602_10 PR GCCAGCTGTA
GATCTGGG
rs833061 C_1647381_10 PR GAGTGTGTGC
GTTGGAGC
rs1570360 C_1647379_10 PR AGCCCGGGCC
GGGCTGAG
rs2010963 C_8311614_10 5′-UTR CGCGCGGGCG
GACAGGGG
rs3025039 C_16198794_10 3′-UTR GCATTCCCGG
GGTCCCTC
PR is Promoter Region, 5′-UTR is 5′-Untranslated Region, 3′-UTR is 3′-Untranslated Rassociations for endometriosis were estimated by the
odds ratio (OR) with 95% confidence interval (95% CI).
Confounding factors that could potentially influence the
risk for endometriosis (P = 0.20) were taken into account
in unconditional logistic regression models. All statistical
analyses were conducted using Statistical Package for
Social Sciences (SPSS Inc., Chicago, IL, USA) for Win-
dows, version 15.0 and a P value less than 0.05 was con-
sidered statistically significant.
Results
No significant difference was observed in the mean age
between the endometriosis patients (35.8 ± 8.6) and the
control group (34.5 ± 6.4). Conversely, BMI, parity, num-
ber of spontaneous abortion, infertility and all preopera-
tive endometriosis symptoms were significantly different
between the two groups (Table 2). There was a predom-
inance of low or normal BMI values (≤24.9) among
endometriosis patients (75.1%), whereas controls had a
predominance of overweight or obesity (58.4%), with
3.4% of patients showing morbid obesity (BMI ≥ 40). The
distribution of endometriotic patients according to the
worst endometriotic lesion was as follows: DIE (151 pa-
tients; 83.0%) and not DIE (31 patients; 17.0%).
The VEGF -2578C > A, −460 T > C, −1154G > A,
+405G > C, +936C > T SNPs were in HWE in the overall
study population and in each group (cases and controls).
Figure 1 and Table 3 show, respectively, the minor allelic
and genotypic frequencies of the VEGF SNPs. Significant
differences in the allele and genotype frequencies were
observed between the two groups with respect to the
-1154G > A (P = 0.005 and P = 0.01, respectively). By
contrast, no significant differences were detected in al-
lele or genotype distribution of the -2578C > A, −460
T > C +405G > C, +936C > T SNPs between endometri-
osis patients and controls. The analysis of risk associa-























Table 2 Demographics and clinical characteristics of the
endometriosis patients and controls
Variable Controls Endometriosis P valueb
No (%) No (%)
BMI
<18.5 3 (3.4) 13 (7.7) <0.001
18.5≤ BMI≤ 24.9 31 (34.8) 113 (67.3)
25≤ BMI≤ 29.9 25 (28.1) 31 (18.5)
30≤ BMI < 40 27 (30.3) 11 (6.5)
≤ 40 3 (3.4) 0 (0)
Parity
0 21 (22.1) 116 (66.3) <0.001
1 14 (14.7) 35 (20.0)
2 26 (27.4) 18 (10.3)
≤ 3 34 (35.8) 6 (3.4)
Spontaneous abortion 21 (22.8) 22 (12.6%) 0.032
Infertility
No 88 (92.6) 93 (53.1) <0.001
Primary 6 (6.3) 60 (34.3)
Secondary 1 (1.1) 22 (12.6)
Symptoma
Dysmenorrhoea 21 (22.3) 91 (51.7) <0.001
Non-cyclic chronic pelvic pain 36 (38.3) 91 (51.7) 0.036
Deep dyspareunia 12 (12.9) 100 (57.5) <0.001
BMI is Body mass index. aA patient can have more than one concomitant
symptom; bChi-Square Test or Fisher’s exact test.
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risk for individuals with any variant genotype (GA+AA), or
an approximate 6-fold increased risk for individuals with the
homozygous variant genotype AA. Although no statistically


























Figure 1 Allelic frequencies of VEGF polymorphism in cases and contthe heterozygous variant genotype (GA), a codominance
model was inferred for the -1154G>A polymorphism
(Ptrend = 0.008).
Haplotypes of the VEGF gene were determined for all
patients and also for endometriosis cases and controls sep-
arately. The results revealed that SNPs -2578C >A,
−460 T > C, −1154G > A and +405G > C were in strong
linkage disequilibrium, forming a single haploblock, while
+936C > T was not linked to the other SNPs (Figure 2).
Therefore, haplotype analysis was only conducted between
VEGF -2578C >A, −460 T > C, −1154G >A and +405G >
C SNPs, and six haplotypes were inferred (Table 5). There
was negative risk association for the development of endo-
metriosis for the haplotypes CCGG and ATGG, when
compared with the reference haplotype CTGG, either con-
sidering all cases, only DIE patients or stages III-IV of
endometriosis. In addition, the haplotype ATGG showed
negative risk associations for the development of endo-
metriosis when considering all cases or DIE, but not stages
III-IV, whereas the haplotype CTGC was protective only
for the development of stages III-IV.Discussion
The pathogenesis and the molecular mechanisms that
underlie the development of endometriosis have trou-
bled investigators through many years, remaining an en-
igma. Endometriosis is regarded as a complex trait in
which genetic and environmental factors contribute to
the disease heterogeneous phenotype. Regarding the epi-
demiological evaluation of the study population, we ob-
served that women with endometriosis have lower BMI
and are less frequently obese than control subjects. Our
results corroborate previous findings [25-29], although
the reason for inverse correlation between BMI andControls
Endometriosis
05
rols. P value from Chi-square test (Pearson p-value).
Table 3 Genotypic distribution of VEGF SNPs in
endometriosis patients and controls
SNP Population N* Genotypic distribution N (%) P χ2
−2578C > A CC CA AA
Controls 111 50 (45.0) 47 (42.3) 14 (12.7) 0.19
Cases 178 61 (34.3) 90 (50.6) 27 (15.1)
−460 T > C TT TC CC
Controls 107 39 (36.4) 51 (47.7) 17 (15.9) 0.50
Cases 179 54 (30.2) 97 (54.2) 28 (15.6)
−1154G > A GG GA AA
Controls 106 74 (69.8) 30 (28.3) 2 (1.9) 0.01
Cases 161 90 (55.9) 56 (34.8) 15 (9.3)
+405G > C GG GC CC
Controls 110 38 (34.6) 56 (50.9) 16 (14.5) 0.16
Cases 181 83 (45.9) 75 (41.4) 23 (12.7)
+936C > T CC CT TT
Controls 95 67 (70.5) 27 (28.4) 1 (1.1) 0.63
Cases 165 120 (72.8) 41 (24.8) 4 (2.4)
N* is the number of examined samples of cases and controls for each SNP.
Differences in sample sizes are due to available data from PCR amplification
for each SNP. P χ2 is P from Chi-square test (Pearson p-value) or Fisher’s
exact test.
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that genetic factors contributing to endometriosis may
also be linked to BMI [30,31]. Although epidemiological
data can be used to better understand the endometriosis,
further studies should investigate the genetics, environ-
mental and physiopathological basis of the decreased
BMI in women with endometriosis.
Because angiogenesis represents a critical step in the
establishment and pathogenesis of endometriosis, this
process has been viewed as a potential new target to bet-
ter define the mechanisms that cause the disease. A largeTable 4 Association analyses of the -1154G > A VEGF polymor
without disease
-1154G > A Controls Cases OR (95% IC)b
(n = 106) (n = 161)
N (%) N (%)
Genotypes
GG 74 (69.8) 90 (55.9) 1a
GA 30 (28.3) 56 (34.8) 1.54 (0.90 - 2.63)
AA 2 (1.9) 15 (9.3) 6.17 (1.37 - 27.8)
Non-GG (GA + AA) 32 (30.2) 71 (44.1) 1.82 (1.09 - 3.06)
Allele
G 178 (84.0) 236 (73.3) 1a
A 34 (16.0) 86 (26.7) 1.90 (1.23 - 2.97)
OR is odds ratio, CI is confidence interval. aReference Group; bControls vs. Cases (Al
patients (DIE); dControls vs. Moderate or severe endometriosis patients (stages III or
genotyped for -1154G > A SNP.number of studies have observed that VEGF was signifi-
cantly higher in women with endometriosis, which sup-
ported a key role for VEGF in the pathological
angiogenesis in endometriosis [9-11]. Polymorphisms in
VEGF may alter protein concentrations, influence the
process of angiogenesis and relate to inter-individual
variation in the risk of endometriosis. The promoter, and
the 5’- and 3’- UTR of the VEGF gene contain key regu-
latory elements, which contribute to the high variability
in VEGF production among tissues [14,32,33].
The inheritable susceptibility to endometriosis justifies
the growing interest in identifying genetic polymor-
phisms that could lead to an increased risk or severity of
the disease, in order to provide additional support for
treatment planning. The present results indicate a posi-
tive association between VEGF -1154G > A and the risk
of developing endometriosis, which is maintained when
considering only the cases of DIE or stages III-IV. Such
risk association was not observed previously [34-36].
Thus, Liu et al. [34] proposed that the -1154AA geno-
type decreased endometriosis risk compared to the
-1154GG genotype, whereas the latter reports showed
no difference in the distribution of VEGF -1154G > A ge-
notypes between cases and controls [35,36]. Neverthe-
less, recent studies suggest that the VEGF -1154G > A
SNP poses an increased risk of recurrent spontaneous
abortion [37,38]. Because such studies did not evaluate
the occurrence of endometriosis as a possible cause of
the recurrent spontaneous abortions, it cannot be ex-
cluded as a confounding factor in the association ana-
lyses. In addition, it has been reported that the
frequency of the VEGF -1154G > A SNP in Brazilians
might be different between individuals self-identified as
“Blacks” or “Whites” [39]. The present study did not col-
lect information on race or skin color. However, all indi-
viduals came from the same region of Brazil, had similarphism in endometriosis patients compared with women
DIE Cases OR (95% IC)c Stages III-IV OR (95% IC)d
(n = 131) (n = 97)
N (%) N (%)
75 (57.3) 1a 56 (57.7) 1a
44 (33.6) 1.45 (0.82 - 2.54) 29 (29.9) 1.28 (0.69 - 2.37)
12 (9.1) 5.92 (1.28 - 27.4) 12 (12.4) 7.93 (1.70 - 36.9)
56 (42.7) 1.73 (1.01 - 2.96) 41 (42.3) 1.69 (0.95 - 3.02)
194 (74.1) 1a 141 (72.7) 1a
68 (25.9) 1.83 (1.16 - 2.90) 53 (27.3) 1.97 (1.21 - 3.19)
l patients with endometriosis); cControls vs. Deeply infiltrating endometriosis
IV). Due to insufficient DNA samples, some of the patients were not
Figure 2 Haplotype association analysis for the five VEGF polymorphisms in a Brazilian women. Number in boxes indicates decimal places
of D’. A Haplotype association analysis in all patients Brazilian women; B cases with endometriosis and C controls were estimated utilising
Haploview program based on the Expectation-Maximization algorithm. There was a strong linkage disequilibrium patterns across the -2578C>A
(lane 1), -460T>C (lane 2), -1154G>A (lane 3) and +405G>C (lane 4) VEGF SNPs of the three studies groups, while +936C>T (lane 5) was not linked
to the other polymorphisms.
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hospitals, when assigned for laparoscopic procedures, re-
gardless of the therapeutic indication. Therefore, no
major racial or color differences is expected between
cases and controls, which had equal access to the public
health system.
With regards to the other four VEGF SNPs (−2578C >
A, −460 T < C, +405G > C, +936C < T), our results
suggest no significant effect on the susceptibility to
endometriosis. It is noteworthy that our result is in
agreement with Zhao and colleagues [40], which sug-
gested no evidence for an association between endomet-
riosis and the VEGF -2578C > A, −460 T < C, +405G > C
and +936C < T SNPs, when considered together in a
larger number (958 cases and 959 controls) of Australian
women. Such findings appear to be corroborated by
other studies which evaluated the different VEGF SNPs
independently from their effect on the risk of endometri-
osis in different populations, and found no significant as-
sociations with -2578C>A [16,40], −460 T<C [16,34,40-48],
+405G>C [16,35,40,43,44,49,50] or +936C<T [34,35,40,51].
Nevertheless, results from a meta-analysis suggest that the
VEGF -2578C > A might be protective for the develop-
ment of endometriosis [18], whereas +936C > T was
pointed as a risk factor [16-18]. The increased risk of
endometriosis for +936C < T was found independently on
a single study, although the SNP showed no correlation
with VEGF mRNA in endometriosis lesions or VEGF pro-
tein levels in peritoneal fluid [44]. Accordingly, Kim and
colleagues [51] showed a lack of association between
+936C < T genotypes and serum VEGF levels in endomet-
riosis patients and controls.
The discrepancies between different studies involving
the impact of VEGF SNPs on the susceptibility to endo-
metriosis may be caused by different allele frequencies
and heterogeneity in the study populations, besidesenvironmental backgrounds. A strong point of our study
is that all patients recruited (cases and controls) were
surgically evaluated to explore for endometriosis. The
histological confirmation of endometriosis was required
to define cases, whereas controls had no visible ectopic
endometrium sites to excluding possibly asymptomatic
endometriosis. As a limitation, our controls included
women with other non-endometriosis gynecological dis-
eases, and might provide lower risk estimates if they are
also associated with the polymorphisms under study.
As far as we know, the present work is the first study
to focus on the possible contribution of the five most
studied VEGF SNPs (−2578C > A, −460 T > C, −1154G
> A, +405G > C and +936C < T) and its haplotypes on
the susceptibility of endometriosis. In agreement with
previous studies, −2578C > A, −460 T > C, −1154G > A
[34] and -2578C > A, −1154G > A, +405G > C [35] were
in linkage disequilibrium, while the +936C < T was vis-
ibly physically far, and had low LD with the other 4
markers in the gene [34,35]. Only three studies reported
association between VEGF haplotypes and susceptibility
to endometriosis; however, the haplotypes with only two
[41,46] or three SNPs [34,35] were evaluated. In the
present study, we observed negative risk associations
with the development of endometriosis for the haplo-
types CTGC (only for stages III-IV), ATGG (for all cases
combined or DIE), and CCGG haplotype (for all condi-
tions). The haplotype ACAG, which was the only one
containing the -1154A allele showed a non-significant
positive risk association for endometriosis, in all condi-
tions evaluated. Taken together, the results suggest that
the effects of VEGF haplotypes in the risk of endometri-
osis are more significant and clinically relevant than
those of each SNP evaluated separately. It is becoming
increasingly important to derive data from different pop-
ulations to build a database which can then be used in
Table 5 Haplotype distributions of VEGF polymorphisms in cases and controls and their association with the risk of developing endometriosis
-2578C > A/ -460
T > C/ -1154G
> A/ +405G >
C VEGF haplotypes
Controls All Cases P valueb OR (95% CI)c DIE Cases P valueb OR (95% IC)d Stages
III-IV
P valueb OR (95% IC)e
(N = 112) (N = 182) (N = 151) (N = 110)
N (%)N (%)No (%) No (%)
CTGG 42 (18.7) 85 (23.4) 1a 69 (22.9) 1a 55 (25.0) 1a
CTGC 90 (40.1) 121 (33.2) 0.10 0.66 (0.42 – 1.05) 104 (34.4) 0.18 0.70 (0.44 – 1.13) 69 (31.3) 0.05 0.58 (0.35 – 0.97)
ACAG 36 (16.0) 96 (26.4) 0.38 1.32 (0.77 – 2.24) 78 (25.8) 0.40 1.32 (0.76 – 2.29) 58 (26.4) 0.58 1.23 (0.69 – 2.19)
ACGG 37 (16.5) 51 (14.0) 0.23 0.68 (0.39 – 1.19) 42 (13.9) 0.27 0.69 (0.38 – 1.24) 31 (14.1) 0.21 0.64 (0.34 – 1.19)
CCGG 15 (6.7) 11 (3.0) 0.03 0.36 (0.15 – 0.86) 9 (3.0) 0.05 0.37 (0.15 – 0.90) 7 (3.2) 0.05 0.35 (0.13 – 0.95)
ATGG 4 (2.0) 0 (0.0) 0.03 - 0 (0.0) 0.05 - 0 (0.0) 0.09 -
OR is odds ratio, CI is confidence interval. aReference Group; bChi-Square Test or Fisher’s exact test; cControls vs. Cases (All patients with endometriosis); dControls vs. Deeply infiltrating endometriosis patients (DIE);
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genetic and environmental factors affecting risk to devel-
opment endometriosis.
Conclusion
In conclusion, our findings with VEGF SNPs and endo-
metriosis in Brazilian women indicate a risk association
for the polymorphism -1154G > A, and protective effect
for the haplotype CCGG. This is the first study to evalu-
ate the combined influence of the five most common
VEGF SNPs. Therefore, further studies on the functional
relevance of the VEGF polymorphisms and exposure to
environmental factors in endometriosis are required to
confirm our observations.
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